iX Biopharma says it is on track to produce its first commercial batch of wafers in July and expects to benefit from “improved operational efficiency and economies of scale”.
Specialty pharmaceutical company iX Biopharma has announced that it will expand its current wafer production capacity at its manufacturing facility in Australia.
The expansion follows the installation and commissioning of new freeze-dry production equipment, which the company says will boost the production of its WaferiX sublingual wafers by up to six times the current capacity.
